Development of Peru-15 (CholeraGarde^®), a live-attenuated oral cholera vaccine: 1991–2009

References

• Chaignat CL. What about cholera vaccines? Expert Rev. Vaccines7(4), 403–405 (2008).
   PubMed Web of Science ®Google Scholar
• Deen JL, von Seidlein L, Sur D et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl. Trop. Dis.2(2), e173 (2008).
   PubMed Web of Science ®Google Scholar
• Lopez AL, Clemens JD, Deen J, Jodar L. Cholera vaccines for the developing world. Hum. Vaccin.4(2), 165–169 (2008).
   PubMed Web of Science ®Google Scholar
• Gaffga NH, Tauxe RV, Mintz ED. Cholera: a new homeland in Africa? Am. J. Trop. Med. Hyg.77(4), 705–713 (2007).
   PubMed Web of Science ®Google Scholar
• Kapp C. Zimbabwe’s humanitarian crisis worsens. Lancet373(9662), 447 (2009).
   PubMed Web of Science ®Google Scholar
• Pruzzo C, Vezzulli L, Colwell RR. Global impact of Vibrio cholerae interactions with chitin. Environ. Microbiol.10(6), 1400–1410 (2008).
   PubMed Web of Science ®Google Scholar
• Colwell RR. Global climate and infectious disease: the cholera paradigm. Science274(5295), 2025–2031 (1996).
   PubMed Web of Science ®Google Scholar
• Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet363(9404), 223–233 (2004).
   PubMed Web of Science ®Google Scholar
• Islam MS, Sharker MA, Rheman S et al. Effects of local climate variability on transmission dynamics of cholera in Matlab, Bangladesh. Trans. R. Soc. Trop. Med. Hyg.103(11), 1165–1170 (2009).
   PubMed Web of Science ®Google Scholar
• WHO. Cholera vaccines: a new public health tool? World Health Organization, Geneva, Switzerland; WHO/CDS/CPE/ZFK/2004.5 (2004).
   Google Scholar
• WHO. Oral cholera vaccine use in complex emergencies: what next? WHO meeting, Cairo, Egypt. WHO/CDS/NTD/IDM/2006.2 (2006).
   Google Scholar
• Chaignat CL, Monti V, Soepardi J et al. Cholera in disasters: do vaccines prompt new hopes? Expert Rev. Vaccines7(4), 431–435 (2008).
   PubMed Web of Science ®Google Scholar
• Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med.4(11), e336 (2007).
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, von Seidlein L et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet366(9479), 44–49 (2005).
   PubMed Web of Science ®Google Scholar
• Graves P, Deeks J, Demicheli V, Pratt M, Jefferson T. Vaccines for preventing cholera. Cochrane Database Syst. Rev.4, CD000974 (2000).
   Google Scholar
• Clemens J, Rao M, Sack D et al. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines. Am. J. Epidemiol.142(7), 759–764 (1995).
   PubMed Web of Science ®Google Scholar
• Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis.6(6), 361–373 (2006).
   PubMed Web of Science ®Google Scholar
• Trach DD, Cam PD, Ke NT et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull. World Health Organ.80(1), 2–8 (2002).
   PubMed Web of Science ®Google Scholar
• Mahalanabis D, Lopez AL, Sur D et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One3(6), e2323 (2008).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine11(2), 207–212 (1993).
   PubMed Web of Science ®Google Scholar
• Kapper JB, Tacket CO. Attenuated Vibrio cholerae strains as live oral cholera vaccines and vectors. In: New Generation Vaccines. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (Eds.). Marcel Dekker, Inc., NY, USA, 511–517 (2004).
   Google Scholar
• Honda T, Finkelstein RA. Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc. Natl Acad. Sci. USA76(4), 2052–2056 (1979).
   PubMed Web of Science ®Google Scholar
• Levine MM, Black RE, Clements ML et al. Texas Star-SR: attenuated ‘Vibrio cholerae’ oral vaccine candidate. Dev. Biol. Stand.53, 59–65 (1983).
   PubMedGoogle Scholar
• Levine MM, Tacket CO. Recombinant live cholera vaccines. In: Vibrio cholerae and Cholera: Molecular to Global Perspectives. Wachsmuth IK, Blake PA, Olsvik O (Eds). American Society for Microbiology Press, Washington DC, USA, 395–414 (1994).
   Google Scholar
• Levine MM, Kaper JB, Herrington D et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet2(8609), 467–470 (1988).
   PubMed Web of Science ®Google Scholar
• Mekalanos JJ, Swartz DJ, Pearson GD, Harford N, Groyne F, de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature306(5943), 551–557 (1983).
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Butron B, Seas C et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun.61(9), 3994–3997 (1993).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Cohen MB, Wasserman SS et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun.67(12), 6341–6345 (1999).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Herrington D et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect. Immun.56(1), 161–167 (1988).
   PubMed Web of Science ®Google Scholar
• Simanjuntak CH, O’Hanley P, Punjabi NH et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J. Infect. Dis.168(5), 1169–1176 (1993).
   PubMed Web of Science ®Google Scholar
• Su-Arehawaratana P, Singharaj P, Taylor DN et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis.165(6), 1042–1048 (1992).
   PubMed Web of Science ®Google Scholar
• Suharyono, Simanjuntak C, Witham N et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5–9-year-old Indonesian children. Lancet340(8821), 689–694 (1992).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev. Vaccines5(4), 483–494 (2006).
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine18(22), 2399–2410 (2000).
   PubMed Web of Science ®Google Scholar
• Calain P, Chaine JP, Johnson E et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine22(19), 2444–2451 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Tacket CO, Losonsky G et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun.65(9), 3852–3856 (1997).
   PubMed Web of Science ®Google Scholar
• Benitez JA, Garcia L, Silva A et al. Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infect. Immun.67(2), 539–545 (1999).
   PubMed Web of Science ®Google Scholar
• Garcia L, Jidy MD, Garcia H et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect. Immun.73(5), 3018–3024 (2005).
   PubMed Web of Science ®Google Scholar
• Thungapathra M, Sharma C, Gupta N et al. Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model. Immunol. Lett.68(2–3), 219–227 (1999).
   PubMed Web of Science ®Google Scholar
• Liang W, Wang S, Yu F et al. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect. Immun.71(10), 5498–5504 (2003).
   PubMed Web of Science ®Google Scholar
• Kenner JR, Coster TS, Taylor DN et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis.172(4), 1126–1129 (1995).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Killeen KP, Hack DC et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J. Infect. Dis.170(6), 1518–1523 (1994).
   PubMed Web of Science ®Google Scholar
• Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science272(5270), 1910–1914 (1996).
   PubMed Web of Science ®Google Scholar
• Sack DA, Sack RB, Shimko J et al. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J. Infect. Dis.176(1), 201–205 (1997).
   PubMed Web of Science ®Google Scholar
• Faruque SM, Asadulghani, Alim AR, Albert MJ, Islam KM, Mekalanos JJ. Induction of the lysogenic phage encoding cholera toxin in naturally occurring strains of toxigenic Vibrio cholerae O1 and O139. Infect. Immun.66(8), 3752–3757 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen MB, Giannella RA, Bean J et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun.70(4), 1965–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine25(2), 231–238 (2007).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J. Infect. Dis.192(4), 573–579 (2005).
   PubMed Web of Science ®Google Scholar
• Sack DA, Qadri F, Svennerholm AM. Determinants of responses to oral vaccines in developing countries. Ann. Nestlé [Engl.],66, 71–79 (2008).
   Google Scholar
• Sack DA, Shimko J, Sack RB et al. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect. Immun.65(6), 2107–2111 (1997).
   PubMed Web of Science ®Google Scholar
• Svennerholm AM, Holmgren J, Ouchterloney O. An agar plaque method for quantitation of vibriocidal antibodies. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol.79(3), 448 (1971).
   PubMedGoogle Scholar
• Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J. Infect. Dis.169(3), 709–710 (1994).
   PubMed Web of Science ®Google Scholar
• Chowdhury F, Khan AI, Harris JB et al. A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr. Infect. Dis. J.27(11), 986–992 (2008).
   PubMed Web of Science ®Google Scholar
• Harris AM, Bhuiyan MS, Chowdhury F et al. Antigen specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect. Immun.77(9), 3850–3856 (2009).
   PubMed Web of Science ®Google Scholar
• Lucas ME, Deen JL, von Seidlein L et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med.352(8), 757–767 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C. Intestinal antibody responses to oral vaccination in HIV-infected individuals. AIDS7(8), 1087–1091 (1993).
   PubMed Web of Science ®Google Scholar
• Ortigao-de-Sampaio MB, Shattock RJ, Hayes P et al. Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS12(14), F145–F150 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Gilks CF, Ojoo S et al. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS8(6), 779–785 (1994).
   PubMed Web of Science ®Google Scholar
• Perry RT, Plowe CV, Koumare B et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull. World Health Organ.76(1), 63–71 (1998).
   PubMed Web of Science ®Google Scholar
• Glass RI, Svennerholm AM, Stoll BJ et al. Effects of undernutrition on infection with Vibrio cholerae O1 and on response to oral cholera vaccine. Pediatr. Infect. Dis. J.8(2), 105–109 (1989).
   PubMed Web of Science ®Google Scholar
• Lagos R, Fasano A, Wasserman SS et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis.180(5), 1709–1712 (1999).
   PubMed Web of Science ®Google Scholar
• Albert MJ, Qadri F, Wahed MA et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J. Infect. Dis.187(6), 909–913 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine27(9), 1433–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Harris JB, Podolsky MJ, Bhuiyan TR et al. Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh. PLoS Negl. Trop. Dis.3(3), e403 (2009).
   PubMed Web of Science ®Google Scholar
• Jones T. Peru-1 5 (AVANT). Curr. Opin. Investig. Drugs5(8), 887–891 (2004).
   PubMedGoogle Scholar
• Clemens JD, Sack DA, Harris JR et al. Field trial of oral cholera vaccines in Bangladesh. Lancet2(8499), 124–127 (1986).
   PubMed Web of Science ®Google Scholar
• Jertborn M, Svennerholm AM, Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine10(2), 130–132 (1992).
   PubMed Web of Science ®Google Scholar
• Roland KL, Cloninger C, Kochi SK et al. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine25(51), 8574–8584 (2007).
   PubMed Web of Science ®Google Scholar
• Sack RB, Siddique AK, Longini IM Jr et al. A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh. J. Infect. Dis.187(1), 96–101 (2003).
   PubMed Web of Science ®Google Scholar
• Faruque AS, Fuchs GJ, Albert MJ. Changing epidemiology of cholera due to Vibrio cholerae O1 and O139 Bengal in Dhaka, Bangladesh. Epidemiol. Infect.116(3), 275–278 (1996).
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis.158(2), 372–377 (1988).
   PubMed Web of Science ®Google Scholar